1620 Investment Advisors Inc. Purchases Shares of 1,402 Lantheus Holdings, Inc. (NASDAQ:LNTH)

1620 Investment Advisors Inc. purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,402 shares of the medical equipment provider’s stock, valued at approximately $125,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Janus Henderson Group PLC increased its holdings in Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after buying an additional 257,022 shares during the period. Geode Capital Management LLC increased its holdings in Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares during the period. Reinhart Partners LLC. increased its holdings in Lantheus by 9.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock valued at $122,280,000 after buying an additional 123,282 shares during the period. Swedbank AB increased its holdings in Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after buying an additional 385,000 shares during the period. Finally, Portolan Capital Management LLC increased its holdings in Lantheus by 6.1% in the 3rd quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider’s stock valued at $73,629,000 after buying an additional 38,776 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Down 1.2 %

Shares of NASDAQ LNTH opened at $97.71 on Friday. The firm’s 50-day simple moving average is $92.67 and its 200 day simple moving average is $96.64. The company has a market cap of $6.69 billion, a price-to-earnings ratio of 16.26 and a beta of 0.38. Lantheus Holdings, Inc. has a 12-month low of $57.92 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Buying and Selling

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock worth $6,110,806 in the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on LNTH shares. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. Truist Financial boosted their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Finally, B. Riley reduced their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.